<?xml version="1.0" encoding="UTF-8"?>
<p>The anti-FIV activity of zidovudine has been assessed in numerous 
 <italic>in vitro</italic> studies in different cell systems [
 <xref rid="B14-vetsci-02-00456" ref-type="bibr">14</xref>,
 <xref rid="B15-vetsci-02-00456" ref-type="bibr">15</xref>,
 <xref rid="B16-vetsci-02-00456" ref-type="bibr">16</xref>,
 <xref rid="B17-vetsci-02-00456" ref-type="bibr">17</xref>,
 <xref rid="B18-vetsci-02-00456" ref-type="bibr">18</xref>,
 <xref rid="B19-vetsci-02-00456" ref-type="bibr">19</xref>,
 <xref rid="B20-vetsci-02-00456" ref-type="bibr">20</xref>,
 <xref rid="B21-vetsci-02-00456" ref-type="bibr">21</xref>,
 <xref rid="B22-vetsci-02-00456" ref-type="bibr">22</xref>,
 <xref rid="B23-vetsci-02-00456" ref-type="bibr">23</xref>,
 <xref rid="B24-vetsci-02-00456" ref-type="bibr">24</xref>,
 <xref rid="B25-vetsci-02-00456" ref-type="bibr">25</xref>,
 <xref rid="B26-vetsci-02-00456" ref-type="bibr">26</xref>]. The first 
 <italic>in vitro</italic> study was carried out in 1989, when North and coworkers showed that zidovudine inhibited FIV replication in Crandell-Rees feline kidney (CRFK) cells. The susceptibility of FIV to zidovudine was similar to that of HIV [
 <xref rid="B27-vetsci-02-00456" ref-type="bibr">27</xref>]. There is evidence that FIV can become resistant to nucleoside analogues, as is the case in HIV. Zidovudine-resistant FIV mutants can arise after only six months of use, and a single-point mutation in the FIV gene is responsible for resistance [
 <xref rid="B10-vetsci-02-00456" ref-type="bibr">10</xref>].
</p>
